Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Passes Above 50 Day Moving Average – Here’s What Happened

Shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $3.47 and traded as high as $3.56. Cryo-Cell International shares last traded at $3.40, with a volume of 20,828 shares traded.

Cryo-Cell International Stock Down 1.7%

The business has a 50 day simple moving average of $3.47 and a two-hundred day simple moving average of $3.56. The firm has a market cap of $27.40 million, a PE ratio of -10.30 and a beta of 0.49.

Cryo-Cell International (NYSEAMERICAN:CCEL) last released its earnings results on Tuesday, April 14th. The company reported $0.01 earnings per share for the quarter. The business had revenue of $7.68 million during the quarter.

Institutional Trading of Cryo-Cell International

An institutional investor recently bought a new position in Cryo-Cell International stock. Susquehanna International Group LLP bought a new position in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned 0.14% of Cryo-Cell International as of its most recent SEC filing. 10.44% of the stock is owned by institutional investors.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.